ENDPOINTS

J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar

Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean biotech’s Stelara biosimilar. The lawsuit, filed Monday in federal district court ...

Feb 25, 2025 - 18:49
 0
J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar
Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean biotech’s Stelara biosimilar. The lawsuit, filed Monday in federal district court ...
Read More

Tags:

Previous Article

Thermo Fisher Beefs Up in Bioprocessing With $4B Acquisition of Solventum Biz Se...

Next Article

5 things help influencers seem authentic

Related Posts

Agios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kids

Agios’ Pyrukynd succeeds in key trial of rare red blood...

Feb 13, 2025  0

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

After passing on M&A offers, Abcuro raises $200M in bid...

Feb 12, 2025  0

Allay Therapeutics raises $45M for ongoing Series D; Encoded’s layoffs

Allay Therapeutics raises $45M for ongoing Series D; En...

Feb 13, 2025  0